The response time to tumour necrosis factor (TNF) inhibitors in patients with psoriatic arthritis is influenced by the location of the affected joint. The shoulder and elbow joints exhibit higher ...

In children born to mothers with chronic inflammatory diseases, the use of TNF inhibitors during pregnancy is not tied to a significant rise in the risk for severe infections.

Children with nonsystemic juvenile idiopathic arthritis who initiated TNF inhibitors when aged 2 years or less showed significant and sustained improvements in disease activity. Early initiation of ...

Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors were at significantly lower risk for hip and spine fractures compared with those receiving only ...

Please provide your email address to receive an email when new articles are posted on . There were “no significant differences” in efficacy, safety or adherence for TNF inhibitors between young- and ...

Real-world data show switching to IL-17 inhibitors after TNF inhibitor failure improves treatment retention compared with TNF ...

Please provide your email address to receive an email when new articles are posted on . Switching from a TNF inhibitor to upadacitinib was superior to cycling TNF inhibitors. Upadacitinib outcomes ...

A randomized controlled trial shows that the TNF inhibitor etanercept improves cerebral blood flow, vascular reactivity, and ...

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry. The ...

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis factor (TNF) inhibitors, ...

Positive clinical data validates commencement of a larger Phase 2b clinical trial in elderly patients post-hip fracture Drug shown to decrease biomarkers associated with TNF-alpha activation in ...

PALM BEACH GARDENS, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc (“Forward”), a biotechnology company developing oral small molecule therapies for inflammation-driven diseases, ...